IKAR-003
Intermediate Age-Related Macular Degeneration (AMD)
Pre-clinicalActive
Key Facts
Indication
Intermediate Age-Related Macular Degeneration (AMD)
Phase
Pre-clinical
Status
Active
Company
About Ikarovec
Ikarovec is an emerging private biotech focused on ophthalmic gene therapies, leveraging a novel bi-functional AAV vector platform. Its lead candidate, IKAR-003, targets intermediate AMD, a large, untreated patient population, and the company recently secured an exclusive option to VectorBuilder's intravitreal capsid technology to enable convenient in-office delivery. With a potential deal value exceeding $1 billion for its lead program, Ikarovec is positioning itself as a leader in developing durable, one-time treatments for retinal diseases, though it remains pre-revenue and at a pre-clinical/early development stage.
View full company profile